Daily Brief Health Care: Samsung Biologics , Revolution Medicines, Sunho Biologics, Arrowhead Pharmaceuticals , Homology Medicines Inc, Glaukos Corp, Haemonetics Corp and more

• Samsung Biologics (207940 KS) reported mixed 1Q24 result, with revenue beating and operating profit missing estimates. Despite robust revenue growth, profitability is under pressure.
• With accumulated orders exceeding $12.5B (vs $12B at the end of 2023), the outlook remains strong. A gradual increase in Plant 4 operations is expected to drive sequential revenue growth.
• On April 23, Samsung Bioepis received marketing approval from European Commission (EC) for Pyzchiva, a biosimilar of Stelara, thereby becoming an early mover in a potential €2.5B market.

• Revolution Medicines reported a decent set of earnings call for the fourth quarter and full year of 2023.
• Throughout the year, Revolution made significant strides, such as revealing the preliminary clinical profiles of two targeted RAS(ON) inhibitors, RMC-6236 and RMC-6291, from Phase I/IIb trials.
• According to data from the Triple Meeting and ESMO Congress, these investigational drugs show promise and support continued development.

• Sunho’s pipeline has high risk and there is a long way to go to demonstrate their final clinical value. It’s highly uncertain if Sunho would bring expected return to investors.
• The entities involved in the process of reorganization were all related parties. Investment from Efung Anhe/Efung Ansheng sparked concern from CSRC. Sunho is required to explain whether there’s any benefit transfer.
• Due to the lack of strong fundamentals, there is no reason for high valuation. It’s not surprising if Sunho’s valuation finally falls below HKD1.53 billion (or even below HK$1 billion).  

• Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a minimum of 20 clinical-stage or marketed products by the year 2025.
• This pledge reflects Arrowhead’s two core goals of maximizing the number of patients aided and the ability to generate enduring value for shareholders.
• Due to the company’s maturing pipeline, Arrowhead is focusing on prioritizing and investing in their internal programs and is actively building late-stage development and commercial infrastructure to focus on the cardiometabolic vertical.

• Homology Medicines is undergoing a reverse merger with an inflammation and immunology company, providing investors with a valuable contingent value right (CVR) on its legacy assets
• Investors participating in a PIPE concurrent with the merger are paying a premium for the new company, excluding the value of the CVR
• The merger is expected to close in Q1, with investors owning a CVR for Homology’s ownership stake in Oxford Biomedica Solutions and potential proceeds from its gene therapy programs

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Glaukos Corporation reported record fourth quarter consolidated net sales of $82.4 million, representing a 16% increase on a reported basis and 15% on a constant currency basis from the previous year.
• For the full year of 2023, the consolidated net sales of approximately $315 million showed an increase of 11% on a reported basis and 12% on a constant currency basis compared to 2022.
• The company also reaffirmed its full year 2024 net sales guidance range of $350 million to $360 million.

• Haemonetics Corporation showed positive financial results, with a third quarter revenue of $336 million, an impressive 10% growth on both reported and organic bases.
• Earnings per diluted share also grew by 22% compared with the previous year, which Haemonetics attributes to above-market growth and the successful achievement of important long range plan milestones.
• The conference call presentation highlighted the revenue increases across segments, with the plasma revenue growing by 8% in the third quarter and the Hospital business revenue growth skyrocketing by an impressive 22%.